- Home
- FBIO vs CGTX Comparison
FBIO vs CGTX Comparison
Compare FBIO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FBIO | CGTX |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.9M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FBIO | CGTX |
|---|---|---|
| Price | $3.74 | $1.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $16.50 | $3.33 |
| AVG Volume (30 Days) | ★ 1.2M | 938.8K |
| Earning Date | 11-14-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $62,303,000.00 | N/A |
| Revenue This Year | $29.71 | N/A |
| Revenue Next Year | $49.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.33 | $0.22 |
| 52 Week High | $4.53 | $3.83 |
Technical Indicators
Market Signals| Indicator | FBIO | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.72 | 49.06 |
| Support Level | $3.25 | $1.37 |
| Resistance Level | $4.53 | $1.50 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 38.88 | 56.25 |
Price Performance
Historical ComparisonAbout FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.